{
    "xml": "<topic id=\"PHP4194\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/pioglitazone\" basename=\"pioglitazone\" title=\"PIOGLITAZONE\">\n<title>PIOGLITAZONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_911\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/thiazolidinediones/pioglitazone\">Pioglitazone</xref>\n</p>\n<data name=\"vtmid\">326058001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_198132768\" title=\"Thiazolidinediones\">Thiazolidinediones</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP36860\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/pioglitazone\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>The thiazolidinedione, pioglitazone, reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36845\" outputclass=\"indicationsAndDose\" rev=\"1.17\" parent=\"/drugs/pioglitazone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 15&#8211;30&#8239;mg once daily, adjusted according to response to 45&#8239;mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3&#8211;6 months and regularly thereafter.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36863\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/pioglitazone\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Pioglitazone cardiovascular safety (December 2007 and January 2011)</p>\n<p>Incidence of heart failure is increased when pioglitazone is combined with insulin especially in patients with predisposing factors e.g. previous myocardial infarction. Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs.</p>\n<p>Pioglitazone should not be used in patients with heart failure or a history of heart failure.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Pioglitazone: risk of bladder cancer (July 2011)</p>\n<p>The European Medicines Agency has advised that there is a small increased risk of bladder cancer associated with pioglitazone use. However, in patients who respond adequately to treatment, the benefits of pioglitazone continue to outweigh the risks.</p>\n<p>Pioglitazone should not be used in patients with active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Pioglitazone should be used with caution in elderly patients as the risk of bladder cancer increases with age.</p>\n<p>Before initiating treatment with pioglitazone, patients should be assessed for risk factors of bladder cancer (including age, smoking status, exposure to certain occupational or chemotherapy agents, or previous radiation therapy to the pelvic region) and any macroscopic haematuria should be investigated. The safety and efficacy of pioglitazone should be reviewed after 3&#8211;6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment.</p>\n<p>Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3&#8211;6 months, as above.</p>\n<p>Patients should be advised to report promptly any haematuria, dysuria, or urinary urgency during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36869\" outputclass=\"contraindications\" rev=\"1.6\" parent=\"/drugs/pioglitazone\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">History of heart failure</ph>; <ph outputclass=\"contraindication\">previous or active bladder cancer</ph>; <ph outputclass=\"contraindication\">uninvestigated macroscopic haematuria</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36880\" outputclass=\"cautions\" rev=\"1.20\" parent=\"/drugs/pioglitazone\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">cardiovascular disease or in combination with insulin (risk of heart failure)</ph>; <ph outputclass=\"caution\">elderly (increased risk of heart failure, fractures, and bladder cancer)</ph>; <ph outputclass=\"caution\">increased risk of bone fractures, particularly in women</ph>; <ph outputclass=\"caution\">risk factors for bladder cancer</ph>\r\n</p>\r\n </section>\r\n<section outputclass=\"importantAdvice\">\r\n<title>Cautions, further information</title>\r\n<sectiondiv>\r\n<p>Substitute insulin during peri-operative period (omit pioglitazone on morning of surgery and recommence when eating and drinking normally).</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP36840\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/pioglitazone\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36813\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/pioglitazone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">haematuria</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypoaesthesia</ph>; <ph outputclass=\"sideEffect\">impotence</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Altered blood lipids</ph>; <ph outputclass=\"sideEffect\">bladder cancer</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">hypoglycaemia</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">proteinuria</ph>; <ph outputclass=\"sideEffect\">sweating</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Liver dysfunction</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Rare reports of liver dysfunction; discontinue if jaundice occurs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36835\" outputclass=\"pregnancy\" parent=\"/drugs/pioglitazone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36885\" outputclass=\"breastFeeding\" parent=\"/drugs/pioglitazone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36849\" outputclass=\"hepaticImpairment\" parent=\"/drugs/pioglitazone\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36788\" outputclass=\"monitoringRequirements\" parent=\"/drugs/pioglitazone\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor liver function before treatment and periodically thereafter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36830\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/pioglitazone\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Liver toxicity</p>\n<p>Patients should be advised to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36765\" outputclass=\"nationalFunding\" rev=\"1.6\" parent=\"/drugs/pioglitazone\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> accepts use of pioglitazone (February 2007) with metformin and a sulfonylurea, for patients (especially if overweight) whose glycaemic control is inadequate despite the use of 2 oral hypoglycaemic drugs and who are unable or unwilling to take insulin; treatment should be initiated and monitored by an experienced diabetes physician.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4194-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pioglitazone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76061\" title=\"Tablet\" namespace=\"/drugs/pioglitazone/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85626\" namespace=\"/drugs/metformin-with-pioglitazone\" title=\"METFORMIN WITH PIOGLITAZONE\" count=\"1\" rel=\"backlink\">METFORMIN WITH PIOGLITAZONE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"19\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_911\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/thiazolidinediones/pioglitazone\" title=\"Pioglitazone\" count=\"1\" rel=\"link\">Pioglitazone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76061\" namespace=\"/drugs/pioglitazone/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4194",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/pioglitazone",
    "basename": "pioglitazone",
    "title": "PIOGLITAZONE",
    "interactants": [
        {
            "id": "bnf_int_911",
            "label": "Pioglitazone"
        }
    ],
    "vtmid": "326058001",
    "drugClassification": [
        "Thiazolidinediones"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "The thiazolidinedione, pioglitazone, reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.",
                "html": "<p>The thiazolidinedione, pioglitazone, reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)",
                        "html": "Type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 15&#8211;30 mg once daily, adjusted according to response to 45 mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3&#8211;6 months and regularly thereafter.",
                        "html": "<p>Initially 15&#8211;30&#8239;mg once daily, adjusted according to response to 45&#8239;mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3&#8211;6 months and regularly thereafter.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose of concomitant sulfonylurea or insulin may need to be reduced.",
                "html": "<p>Dose of concomitant sulfonylurea or insulin may need to be reduced.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Pioglitazone cardiovascular safety (December 2007 and January 2011)",
                "textContent": "Incidence of heart failure is increased when pioglitazone is combined with insulin especially in patients with predisposing factors e.g. previous myocardial infarction. Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs.\n\nPioglitazone should not be used in patients with heart failure or a history of heart failure.",
                "html": "<p>Incidence of heart failure is increased when pioglitazone is combined with insulin especially in patients with predisposing factors e.g. previous myocardial infarction. Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs.</p><p>Pioglitazone should not be used in patients with heart failure or a history of heart failure.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "Pioglitazone: risk of bladder cancer (July 2011)",
                "textContent": "The European Medicines Agency has advised that there is a small increased risk of bladder cancer associated with pioglitazone use. However, in patients who respond adequately to treatment, the benefits of pioglitazone continue to outweigh the risks.\n\nPioglitazone should not be used in patients with active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Pioglitazone should be used with caution in elderly patients as the risk of bladder cancer increases with age.\n\nBefore initiating treatment with pioglitazone, patients should be assessed for risk factors of bladder cancer (including age, smoking status, exposure to certain occupational or chemotherapy agents, or previous radiation therapy to the pelvic region) and any macroscopic haematuria should be investigated. The safety and efficacy of pioglitazone should be reviewed after 3&#8211;6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment.\n\nPatients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3&#8211;6 months, as above.\n\nPatients should be advised to report promptly any haematuria, dysuria, or urinary urgency during treatment.",
                "html": "<p>The European Medicines Agency has advised that there is a small increased risk of bladder cancer associated with pioglitazone use. However, in patients who respond adequately to treatment, the benefits of pioglitazone continue to outweigh the risks.</p><p>Pioglitazone should not be used in patients with active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Pioglitazone should be used with caution in elderly patients as the risk of bladder cancer increases with age.</p><p>Before initiating treatment with pioglitazone, patients should be assessed for risk factors of bladder cancer (including age, smoking status, exposure to certain occupational or chemotherapy agents, or previous radiation therapy to the pelvic region) and any macroscopic haematuria should be investigated. The safety and efficacy of pioglitazone should be reviewed after 3&#8211;6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment.</p><p>Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3&#8211;6 months, as above.</p><p>Patients should be advised to report promptly any haematuria, dysuria, or urinary urgency during treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "History of heart failure",
                "html": "History of heart failure"
            },
            {
                "type": "contraindications",
                "textContent": "previous or active bladder cancer",
                "html": "previous or active bladder cancer"
            },
            {
                "type": "contraindications",
                "textContent": "uninvestigated macroscopic haematuria",
                "html": "uninvestigated macroscopic haematuria"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "cardiovascular disease or in combination with insulin (risk of heart failure)",
                "html": "cardiovascular disease or in combination with insulin (risk of heart failure)"
            },
            {
                "type": "cautions",
                "textContent": "elderly (increased risk of heart failure, fractures, and bladder cancer)",
                "html": "elderly (increased risk of heart failure, fractures, and bladder cancer)"
            },
            {
                "type": "cautions",
                "textContent": "increased risk of bone fractures, particularly in women",
                "html": "increased risk of bone fractures, particularly in women"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for bladder cancer",
                "html": "risk factors for bladder cancer"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Substitute insulin during peri-operative period (omit pioglitazone on morning of surgery and recommence when eating and drinking normally).",
                "html": "<p>Substitute insulin during peri-operative period (omit pioglitazone on morning of surgery and recommence when eating and drinking normally).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haematuria",
                        "html": "haematuria",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoaesthesia",
                        "html": "hypoaesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "impotence",
                        "html": "impotence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Altered blood lipids",
                        "html": "Altered blood lipids",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bladder cancer",
                        "html": "bladder cancer",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypoglycaemia",
                        "html": "hypoglycaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "proteinuria",
                        "html": "proteinuria",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Liver dysfunction",
                        "html": "Liver dysfunction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Liver toxicity",
                "textContent": "Rare reports of liver dysfunction; discontinue if jaundice occurs.",
                "html": "<p>Rare reports of liver dysfunction; discontinue if jaundice occurs.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;toxicity in animal studies.",
                "html": "<p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor liver function before treatment and periodically thereafter.",
                "html": "<p>Monitor liver function before treatment and periodically thereafter.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Liver toxicity",
                "textContent": "Patients should be advised to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop.",
                "html": "<p>Patients should be advised to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium accepts use of pioglitazone (February 2007) with metformin and a sulfonylurea, for patients (especially if overweight) whose glycaemic control is inadequate despite the use of 2 oral hypoglycaemic drugs and who are unable or unwilling to take insulin; treatment should be initiated and monitored by an experienced diabetes physician.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> accepts use of pioglitazone (February 2007) with metformin and a sulfonylurea, for patients (especially if overweight) whose glycaemic control is inadequate despite the use of 2 oral hypoglycaemic drugs and who are unable or unwilling to take insulin; treatment should be initiated and monitored by an experienced diabetes physician.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76061",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85626",
                "label": "METFORMIN WITH PIOGLITAZONE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_911",
                "label": "Pioglitazone",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76061",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}